Home > List All Publishers > Espicom Healthcare Intelligence

Espicom Healthcare Intelligence

For over 15 years, Espicom has been the choice of senior personnel in industry, commerce and government for high quality, reliable and affordable business intelligence. Espicom serves the Telecommunication, Pharmaceutical, and Medical Device industries supplying, in all, more than 7,500 customers in 50 countries worldwide. Espicom is a full service information provider whose portfolio of products range from single company and market profiles to multi-access global deals for Intranets. Whatever your requirement or budget, Espicom has the information solution you need.

List of reports from Espicom Healthcare Intelligence

Protherics Cancer Company Intelligence Report 3/16/2005 \| published by: Espicom Healthcare Intelligence ... UK, manufacturing facilities in Ceredigion, Wales and Rosedale, Australia, and commercial development, clinical development and regulatory facilities in Nashville, TN. The company's manufacturing facilities meet FDA, MCA, TGA and GMP requirements for the manufacture of ... \| more...	$195.00
ONCOGENEX TECHNOLOGIES Cancer Company Intelligence Report 3/18/2005 \| published by: Espicom Healthcare Intelligence ... quickly and efficiently is the result of its ability to unite groups with a common interest in treating cancer: universities, hospitals, clinical networks, companies, granting agencies and investors. This strategy allows the company to conserve ... \| more...	$195.00
Access Pharmaceuticals Cancer Company Intelligence Report 3/16/2005 \| published by: Espicom Healthcare Intelligence ... an emerging pharmaceutical company focused on the development and commercialisation of advanced drug-delivery systems to improve the clinical outcome for both novel and marketed drugs. The company is developing both novel low-development risk product candidates ... \| more...	$195.00
Anosys Cancer Company Intelligence Report 3/16/2005 \| published by: Espicom Healthcare Intelligence ... facilitates each patient's own natural defence against disease. This approach features the administration of dendritic-derived exosomes, well-characterised, naturally-derived vesicles that contain all the components necessary to activate the major immune responses. Anosys has successfully developed ... \| more...	$195.00
Aphton Cancer Company Intelligence Report 3/16/2005 \| published by: Espicom Healthcare Intelligence ... proprietary active immunisation and monoclonal antibody (MAb) technologies. These technologies are based on key discoveries made by Aphton as well as its deep understanding of the central role of gastrin, a naturally-occurring hormone, and gastrin ... \| more...	$195.00
Arqule Cancer Company Intelligence Report 3/16/2005 \| published by: Espicom Healthcare Intelligence ... effective cancer drugs with reduced toxicities compared to conventional cancer chemotherapeutics. It develops cancer therapies based on its innovative and proprietary Activated Checkpoint Therapy (ACT) platform and its traditional strength in small-molecule chemistry. ArQule also ... \| more...	$195.00
Bristol-Myers Squibb Cancer Company Intelligence Report 3/16/2005 \| published by: Espicom Healthcare Intelligence ... office-based oncologists in the US. OTN’s objective is to address the cost containment needs and reduce the administrative burdens of office-based oncologists by attempting to serve as a convenient, cost-effective, single source of supply of ... \| more...	$195.00
Cel-Sci Cancer Company Intelligence Report 3/16/2005 \| published by: Espicom Healthcare Intelligence ... to direct the body to choose a specific immune response. The heteroconjugate technology, referred to as LEAPS (Ligand Epitope Antigen Presentation System), is intended to selectively stimulate the human immune system to more effectively fight ... \| more...	$195.00
Kirin Brewery Cancer Company Intelligence Report 3/16/2005 \| published by: Espicom Healthcare Intelligence ... and internal business units called “companies.” Kirin Brewery operates both as a business company managing the Japanese beer and happo-shu (low-malt beer) business, and as a holding company overseeing each business and strengthening group operations. \| more...	$195.00
Peregrine Pharmaceuticals Cancer Company Intelligence Report 3/16/2005 \| published by: Espicom Healthcare Intelligence ... nervous system. The company's product development focus is on novel proteins and biochemcial pathways related to cellular regulation and cell cycle abnormalities in oncology as well as neurodegenerative diseases, particularly Alzheimer's disease and Parkinson's disease. \| more...	$195.00
Intarcia Therapeutics Cancer Company Intelligence Report (FORMERLY BIOMEDICINES) 3/16/2005 \| published by: Espicom Healthcare Intelligence ... but changed its name to Intarcia Therapeutics on 27th September 2004. While Intarcia may continue development of a drug for the original clinical indication, it also seeks to add value by redirecting development to new ... \| more...	$195.00
Synta Pharmaceuticals Cancer Company Intelligence Report 3/16/2005 \| published by: Espicom Healthcare Intelligence Synta, which commenced operations in July 2001, is a product-focused biopharmaceutical company developing novel, small-molecule drugs for cancer, inflammatory diseases and diabetes. All of its products were developed internally using the company’s chemistry-driven drug-discovery platform. \| more...	$195.00
Biomira Cancer Company Intelligence Report 3/16/2005 \| published by: Espicom Healthcare Intelligence ... competency in immunotherapeutics, designed to stimulate an individual’s immune system to recognise cancer cells and control the growth and spreading of cancers. Biomira's immunotherapeutics programme currently focuses on the development of synthetic vaccines for active ... \| more...	$195.00
Cell Genesys Cancer Company Intelligence Report 3/16/2005 \| published by: Espicom Healthcare Intelligence ... the cancer arena, an extensive patent portfolio and a strong financial position. The company is conducting clinical trials in multiple types of cancer utilising two of its three product platform technologies: GVAX cancer vaccines and ... \| more...	$195.00
Coley Pharmaceutical Cancer Company Intelligence Report 3/16/2005 \| published by: Espicom Healthcare Intelligence ... CpG oligos, as well as to develop an understanding of how these molecules work as they interact with the human immune system. Because of their immunostimulatory properties, Coley believes that its CpG oligo product candidates ... \| more...	$195.00
Vistakon Medical Device Company Intelligence Report 5/30/2012 \| published by: Espicom Healthcare Intelligence ... on products, international activities and R&D, as well as a full, in-depth five year financial analysis. An introduction to each report and a full table of contents is provided for review. More than 60 Medical ... \| more...	$255.00
Ethicon Endo-Surgery Medical Device Company Intelligence Report 4/30/2012 \| published by: Espicom Healthcare Intelligence ... on products, international activities and R&D, as well as a full, in-depth five year financial analysis. An introduction to each report and a full table of contents is provided for review. More than 60 Medical ... \| more... Search inside this report	$340.00
Actavis Generics Company Intelligence Report 1/11/2011 \| published by: Espicom Healthcare Intelligence ... the business, the most recent quarterly and annual financial results, information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation. ... \| more... Search inside this report	$340.00
Aurobindo Generics Company Intelligence Report 1/11/2011 \| published by: Espicom Healthcare Intelligence ... the business, the most recent quarterly and annual financial results, information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation. ... \| more... Search inside this report	$340.00
Dr Reddy's Laboratories Generics Company Intelligence Report 1/11/2011 \| published by: Espicom Healthcare Intelligence ... the business, the most recent quarterly and annual financial results, information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation. ... \| more... Search inside this report	$340.00
Gedeon Richter Generics Company Intelligence Report 1/11/2011 \| published by: Espicom Healthcare Intelligence ... the business, the most recent quarterly and annual financial results, information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation. ... \| more... Search inside this report	$340.00
KRKA Generics Company Intelligence Report 1/11/2011 \| published by: Espicom Healthcare Intelligence ... the business, the most recent quarterly and annual financial results, information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation. ... \| more... Search inside this report	$340.00
Lupin Generics Company Intelligence Report 1/11/2011 \| published by: Espicom Healthcare Intelligence ... the business, the most recent quarterly and annual financial results, information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation. ... \| more... Search inside this report	$340.00
Ranbaxy Generics Company Intelligence Report 1/11/2011 \| published by: Espicom Healthcare Intelligence ... the business, the most recent quarterly and annual financial results, information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation. ... \| more... Search inside this report	$340.00
Ratiopharm Generics Company Intelligence Report 1/11/2011 \| published by: Espicom Healthcare Intelligence ... the business, the most recent quarterly and annual financial results, information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation. ... \| more... Search inside this report	$340.00

< prev 1 2 3 4 5 6 7 8 9 10 next >